Modulation of central serotonergic neurotransmission by risperidone: Underlying mechanism(s) and significance of action

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 5, 1998, Pages 815-834

  Hertel, Peter ^a   Lindblom, Nina ^a   Nomikos, George G ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dorsal raphe nucleus; Frontal cortex; Microdialysis; Neuroleptic drugs; Serotonin; Single cell recording

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG VEHICLE; FENCLONINE; IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRAZOSIN; RACLOPRIDE; RISPERIDONE; SEROTONIN; SEROTONIN 1A ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG MECHANISM; FRONTAL CORTEX; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; MODULATION; NEUROTRANSMISSION; NONHUMAN; RAT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; AUTORECEPTORS; BRAIN CHEMISTRY; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RISPERIDONE; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 0032126294     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00042-6     Document Type: Article

References (51)

1. ABI-DARGHAM, A., LARUELLE, M., AGHAJANIAN, G.K., CHARNEY, D. and KRYSTAL, J. (1997) The role of serotonin in pathophysiology and treatment of schizophrenia. J. Neuropsych. Clin. Neurosci. 9: 1-17.
2. AGHAJANIAN, G.K. (1995) Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In: Psychopharmacology: the fourth generation of progress, F.E. Bloom, D.J. Kupfer (Eds.), pp 451-60, Raven Press, New York.
3. AGHAJANIAN, G.K., WANG, R.Y. and BARABAN, J. (1978) Serotonergic and non-seretonergic neurons of the dorsal raphe: reciprocal changes in firing induced by peripheral nerve stimulation. Brain Res. 153: 169-175.
4. 1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur. J. Pharmacol. 304: 15-21.
5. BARABAN, J.M. and AGHAJANIAN, G.K. (1980) Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonist. Neuropharmacology. 19: 355-363.
6. BORISON, R.L., PATHIRAJA, P.A., DIAMOND, B.I. and MEIBACH, R.C. (1992) Risperidone: clinical saftey and efficacy in schizophrenia. Psychopharmacol. Bull. 28: 213-218.
7. CHAPUT, Y., LESIEUR, P. and DE MONTIGNY, C. (1990) Effects of short-term serotonin depletion on the efficacy of serotonin neurotransmission: Electrophysiological studies in the rat central nervous system. Synapse. 6; 328-337.
8. CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MACEWAN, G.W., LABELLE, A., BEAUCLAIR, L. and ARNOTT, W. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13: 25-40.
9. CUNNINGHAM, K.A. and LAKOSKI, J.M. (1990) The interaction of cocaine with serotonin dorsal raphe neurons, single-unit extracellular recording studies. Neuropsychopharmacology. 3: 41-50.
10. 1D autoreceptors. Br. J. Pharmacol. 114: 1107-1109.
11. DAVIS, J.M. and JANICAK, P.G. (1996) Risperidone: A new, novel (and better?) antipsychotic. Psychiat. Ann. 26: 78-87.
12. DEUTCH, A.Y., MOGHADDAM, B., INNIS, R.B., KRYSTAL, J.H., AGHAJANIAN, G.K., BUNNEY, B.S. and CHARNEY, D.S. (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4: 121-156.
13. 2-adrenoceptors. Br. J. Pharmacol. 78: 489-505.
14. 2-adrenoceptors on rat central neurons. Eur. J. Pharmacol. 105: 265-272.
15. GALLAGER, D.W. and AGHAJANIAN, G.K. (1976) Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur. J. Pharmacol. 39: 341-355.
16. GARRATT, J.C., CRESPI, F., MASON, R. and MARSDEN, C.A. (1991) Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur. J. Pharmacol. 193: 87-93.
17. 1A autoreceptors and noradrenergic mechanisms. Psychopharmacology. 130: 261-268.
18. GERLACH, J. and PEACOCK, L. (1995) New antipsychotics: the present status, Int. Clin. Psychopharmacol. 10: 39-48.
19. GOFF, D.C., MIDHA, K.K., SARID-SEGAL, O., HUBBARD, J.W. and AMICO, E. (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia Psychopharmacology. 117: 417-423.
20. GOLDMAN, M.B. and JANECEK, H.M. (1990) Adjunctive fluoxetine improves global function in chronic schizophrenia. J. Neuropsych. Clin. Neurosci. 2: 429-431.
21. GÖTHERT, M., HUTH, H. and SCHLICKER, E. (1981) Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 317: 199-203.
22. HERTEL, P., NOMIKOS, G.G., IURLO, M. and SVENSSON, T.H. (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. 124: 74-86.
23. 2 adrenoceptor antagonism. Neuropsychopharmacology. 17: 44-55.
24. HERTEL, P., NOMIKOS, G.G. and SVENSSON, T.H. (1997b) Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br. J. Pharmacol. 122: 1639-1646.
25. 1-adrenoceptors in the inhibition of 5-HT release-1. BMY7378 and prazosin. Neuropharmacology. 34: 615-620.
26. JACOBS, B.L. and AZMITIA, E.C. (1992) Structure and function of the brain serotonin system. Physiol. Rev. 72: 165-229.
27. KANE, J., HONIGFELD, G., SINGER, J. and MELTZER, H.Y. (1988) Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry. 45: 789-796.
28. KOE, B.K. and WEISSMAN, A. (1966) p-Chlorophenylalanine: A specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 154: 499-516.
29. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the brain. Biochem. Pharmacol. 34: 2251-2259.
30. 1A receptors. Eur. J. Pharmacol. 260: 79-83.
31. LEYSEN, J.E., JANSSEN, P.F.M., GOMMEREN, W., WYNANTS, J., PAUWELS, P.J. and JANSSEN, P.A.J. (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41: 494-508.
32. 2 receptors. Psychopharmacology. 112: S40-S54.
33. LITMAN, R.E., SU, T.P., POTTER, W.Z., HONG, W.W. and PICKAR, D. (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry. 168: 571-579.
34. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265: 498-508.
35. 2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 345: 410-416.
36. MCQUADE, R. and SHARP, T. (1997) Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem. 69: 791-796.
37. i values. J. Pharmacol. Exp. Ther. 251: 238-246.
38. 1-adrenoceptors in brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 317: 273-275.
39. MESOTTEN, F., SUY, E., PIETQUIN, M., BURTON, P. and HEYLEN, S. (1989) Therapeutic effect and safety of increaseing dose of risperidone (R64744) in psychotic patients. Psychopharmacology. 99: 445-449.
40. 3 mediated control of dopaminergic function. Psychopharmacology. 112: 60-67.
41. PAXINOS, G. and WATSON, C. (1986) The rat brain in stereotaxic coordinates. 2nd ed., Academic Press, Sydney.
42. 1D receptors in the rat brain. Synapse. 22: 54-62.
43. SCHOTTE, A., JANSSEN, P.F.M., GOMMEREN, W., LUYTEN, W.H.M.L., VAN GOMPEL, P., LESAGE, A.S., DE LOORE, K. and LEYSEN, J.E. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124: 57-73.
44. SHARMA, R.P., SHAPIRO, L.E., KAMATH, S.K., SOLL, E.A., WATANABE, M.D. and DAVIS, J.M. (1997) Acute dietary tryptophan depletion: Effects on schizophrenic positive and negative symptoms. Neuropsychobiology. 35: 5-10.
45. SILVER, H. and NASSAR, A. (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry. 31: 698-704.
46. SPINA, E., DE DOMENICO, P., RUELLO, C., LONGOBARDO, N., GITTO, C., ANCIOME, M., DI ROSA, A.E. and CAPUTI, A.P. (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharamcol. 9: 281-285.
47. STARKE, K., GÖTHERT, M. and KILBINGER, H. (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 69: 864-989.
48. 2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav. 47: 553-557.
49. SVENSSON, T.H., BUNNEY, B.S. and AGHAJANIAN, G.K. (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res. 92: 291-306.
50. VANDERMAELEN, C.P. and AGHAJANIAN, G.K. (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellulary in rat brain slices. Brain Res. 289: 109-119.
51. WANG, R. Y. and AGHAJANIAN, G. (1978) Collateral inhibition of serotonergic neurones in the rat dorsal raphe nucleus: Pharmacological evidence. Neuropharmacology. 17: 819-825.